Expression of CD44 in Triple Negative Breast Cancer and its Correlation with Prognostic Parameters Correlation of CD44 expression in TNBC
Abstract
Background: The study aims to evaluate CD44 expression as a cancer stem cell marker in Triple-negative breast cancer (TNBC) and its correlation with prognostic parameters. Evaluation of CD44 immunoexpression in TNBC is vital for understanding tumour aggressiveness and determining its prognostic value.
Methods: A hospital based cross sectional study of 50 cases of primary triple negative breast cancer patients. The tissue sections were subjected to immunohistochemical examination using CD44 antigen marker. The proportion and intensity of CD44 immunostaining was assessed and correlation with prognostic markers such as histological grade, tumor size and nodal status.
Results: CD44 expression was observed in 40% of the total cases with a statistically significant association with histological grade (p-value= 0.002). Higher CD44 expression was noticed with increasing tumour grade. However, no statistical significance was observed with respect to tumour size and nodal status.
Conclusion: The study suggests that CD44 immunoexpression may serve as a surrogate marker of BCSCs and may hold prognostic value in TNBC patients. However, further studies on larger samples are required to fully understand its role.
Full text article
References
Globocan factsheets 2022, WHO. Available from Internet- https://gco.iarc.who.int/media/globocan/factsheets/populations/900-world-fact-sheet.pdf. (Last Accessed 1st April, 2024).
Globocan factsheets India 2022, WHO. Available from Internet-https://gco.iarc.who.int/media/globocan/factsheets/populations/356-india-fact-sheet.pdf. (Last Accessed 1st April, 2024)
Sarkar S, Akhtar M. Triple Negative Breast Cancer Prevalence in Indian Patients over a Decade: A Systematic Review. Int J Clin Biostat Biom. 2022;8(1):045. doi: 10.23937/2469-5831/1510045
Mehrotra R, Yadav K. Breast cancer in India: Present scenario and the challenges ahead. World J Clin Oncol. 2022;13(3):209-218. doi:10.5306/wjco.v13.i3.209.
Skvortsova I. Cancer Stem Cells: What Do We Know about Them?. Cells. 2021;10(6):1528. doi:10.3390/cells10061528).
E. Charafe-Jauffret, C. Ginestier, F. Iovino et al., “Breast cancer cell lines contain functional cancer stem sells with metastatic capacity and a distinct molecular signature”. Cancer Research. 2009;69(4):1302–1313.
De Beça F F, Caetano P, Gerhard R, Alvarenga CA, Gomes M, Paredes J, et. al. Cancer stem cells markers CD44, CD24 and ALDH1 in breast cancer special histological types. J. Clin. Pathol. 2013;66:187–191. doi: 10.1136/jclinpath-2012-201169.
Ponta H, Sherman L, Herrlich PA. CD44: from adhesion molecules to signalling regulators. Nat Rev Mol Cell Biol. 2003;4:33–45. doi: 10.1038/nrm1004.
Hebbard L, Steffen A, Zawadzki V, Fieber C, Howells N, Moll J, Ponta H, Hofmann M, Sleeman J. CD44 expression and regulation during mammary gland development and function. J Cell Sci. 2000;113:2619–2630.
Almási S, Nagy Á, Krenács T, Lantos T, Zombori T, Cserni G. The prognostic value of stem cell markers in triple-negative breast cancer. Pathol Oncol Res. 2023;29:1611365. doi: 10.3389/pore.2023.1611365.
Xu H, Tian Y, Yuan X, Liu Y, Wu H, Liu Q, et al. Enrichment of CD44 in basal-type breast cancer correlates with EMT, cancer stem cell gene profile, and prognosis. Onco Targets Ther. 2016 Jan 21;9:431-44. doi: 10.2147/OTT.S97192.
Jang MH, Kang HJ, Jang KS, Paik SS, Kim WS. Clinicopathological analysis of CD44 and CD24 expression in invasive breast cancer. Oncol Lett. 2016;12(4):2728-2733. doi:10.3892/ol.2016.4987.
Collina F, Di Bonito M, Li Bergolis V, et al. Prognostic Value of Cancer Stem Cells Markers in Triple-Negative Breast Cancer. Biomed Res Int. 2015;2015:158682. doi:10.1155/2015/158682.
Collins LC. Breast. Rosai and Ackerman Surgical Pathology, 11th edition. Philadelphia: Elsevier; 2017. pp. 1434-527.
Hortobagyi GN, Connolly JL, D’Orsi C Jet al. Breast. In: Amin MB, Edge S, Greene F et al, eds; American Joint Committee on Cancer. AJCC cancer staging manual. 8th ed. New York: Springer; 2017. pp. 589–636.
Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, et al. Identification of Human Triple-Negative Breast Cancer Subtypes and Preclinical Models for Selection of Targeted Therapies. J Clin Invest 2011;121(7):2750–67. doi: 10.1172/JCI45014.
Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature. 2001;414(6859):105-11. doi: 10.1038/35102167.
Thapa R, Wilson GD. The Importance of CD44 as a Stem Cell Biomarker and Therapeutic Target in Cancer. Stem Cells Int. 2016;2016:2087204. doi: 10.1155/2016/2087204.
Liu YX, Wang KR, Xing H, Zhai XJ, Wang LP, Wang W. Attempt Towards a Novel Classification of Triple-Negative Breast Cancer Using Immunohistochemical Markers. Oncol Lett. 2016;12(2):1240–56. doi: 10.3892/ol.2016.4778.
Chekhun SV, Zadvorny TV, Tymovska YO, Anikusko MF, Novak OE, Polishchuk LZ. СD44+/CD24- markers of cancer stem cells in patients with breast cancer of different molecular subtypes. Exp Oncol. 2015;37(1):58-63.
McFarlane S, Coulter JA, Tibbits P, O'Grady A, McFarlane C, Montgomery N et. al. CD44 increases the efficiency of distant metastasis of breast cancer. Oncotarget. 2015;6:11465–11476.
Xu H, Wu K, Tian Y, Liu Q, Han N, Yuan X, et. al. CD44 correlates with clinicopathological characteristics and is upregulated by EGFR in breast cancer. Int J Oncol. 2016;49(4):1343-50. doi: 10.3892/ijo.2016.3639.
Abdoli Shadbad M, Hosseinkhani N, Asadzadeh Z, Derakhshani A, Karim Ahangar N, Hemmat N, et. al. A Systematic Review to Clarify the Prognostic Values of CD44 and CD44+CD24- Phenotype in Triple-Negative Breast Cancer Patients: Lessons Learned and The Road Ahead. Front Oncol. 2021;11:689839. doi:10.3389/fonc.2021.689839.
Zou W, Yang Y, Zheng R, Wang Z, Zeng H, Chen Z, et. al. Association of CD44 and CD24 phenotype with lymph node metastasis and survival in triple-negative breast cancer. Int J Clin Exp Pathol. 2020;13(5):1008-1016.
Obidiro O, Battogtokh G, Akala EO. Triple Negative Breast Cancer Treatment Options and Limitations: Future Outlook. Pharmaceutics. 2023;15(7):1796. doi: 10.3390/pharmaceutics15071796.
Ponti D, Costa A, Zaffaroni N, Pratesi G, Petrangolini G, Coradini D, et al. Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. Cancer Res. 2005;65(13):5506-11. doi: 10.1158/0008-5472.
Authors
Copyright (c) 2024 Archives of Breast Cancer
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright©. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non-Commercial 4.0 International License, which permits copy and redistribution of the material in any medium or format or adapt, remix, transform, and build upon the material for any purpose, except for commercial purposes.